Janssen announced data from 3 real-world analyses for Invokana (canagliflozin) in adults with type 2 diabetes. Results were presented at the 20th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
The first was a retrospective observational study (n=16,613) of adults with type 2 diabetes who had been taking Invokana. Prior to treatment initiation, patients were taking an average of 2.7 antihyperglycemic agents to control their glucose. Use of Invokana had statistically significant increases in the percent of patients who reached A1c goals. Overall, 59.5% of patients achieved an A1c <8% at three months. Also, among patients with baseline blood pressure of at least 140/90mmHg, 60% and 75% achieved blood pressure reduction goals of <140mmHg systolic and <90mmHg diastolic, respectively, after three months.
The second was a retrospective cohort study (n=4,017) of adults with type 2 diabetes who had been taking Invokana. Data showed that the proportion of patients with A1c <8% increased from 39% to 66% at follow-up. The proportion of patients with A1c <7% increased from 13% to 28%. Overall, Invokana demonstrated an average A1c reduction from 8.6% to 7.8%.
The third was a retrospective cohort study (n=268) of adults with type 2 diabetes included i the 2013 Inovalon MORE Registry. Data showed after 120 days of treatment with Invokana, the proportion of patients with A1c <8% increased from 26% at baseline to 38%. Patients with A1c <7% increased from 15% to 31%. In addition, Invokana demonstrated a reduction in A1c from 8.3% to 7.6% (P<0.001).
Invokana is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
For more information visit ispor.org.